
NATURE . COM {
}
Title:
KUS121, a VCP modulator, attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress | Scientific Reports
Description:
Ischemic neural damages cause several devastating diseases, including brain stroke and ischemic retinopathies, and endoplasmic reticulum (ER) stress has been proposed to be the underlying mechanism of the neuronal cell death of these conditions. We previously synthesized Kyoto University substances (KUSs) as modulators of valosin-containing protein (VCP); KUSs inhibit VCP ATPase activity and protect cells from different cell death-inducing insults. Here, we examined the efficacy of KUS121 in a rat model of retinal ischemic injury. Systemic administration of KUS121 to rats with ischemic retinal injury significantly suppressed inner retinal thinning and death of retinal ganglion and amacrine cells, with a significant functional maintenance of visual functions, as judged by electroretinography. Furthermore, intravitreal injection of KUS121, which is the clinically preferred route of drug administration for retinal diseases, appeared to show an equal or better neuroprotective efficacy in the ischemic retina compared with systemic administration. Indeed, induction of the ER stress marker C/EBP homologous protein (CHOP) after the ischemic insult was significantly suppressed by KUS121 administration. Our study suggests VCP modulation by KUS as a promising novel therapeutic strategy for ischemic neuronal diseases.
Website Age:
30 years and 10 months (reg. 1994-08-11).
Matching Content Categories {π}
- Education
- Science
- Insurance
Content Management System {π}
What CMS is nature.com built with?
Custom-built
No common CMS systems were detected on Nature.com, and no known web development framework was identified.
Traffic Estimate {π}
What is the average monthly size of nature.com audience?
π Monumental Traffic: 20M - 50M visitors per month
Based on our best estimate, this website will receive around 42,798,980 visitors per month in the current month.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Nature.com Make Money? {πΈ}
Display Ads {π―}
The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.
Ads are managed by yourbow.com. Particular relationships are as follows:
Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.comReseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.comHow Much Does Nature.com Make? {π°}
Display Ads {π―}
$539,300 per month
Estimations show Nature.com's display ad online revenue falls between $359,553 and $988,772 per month.
Keywords {π}
retinal, ischemic, kus, injury, control, cell, layer, article, group, cells, rats, thickness, retina, pubmed, google, scholar, vcp, insult, fig, doi, rgcs, ganglion, ischemia, days, death, effects, outer, neuroprotective, images, nuclear, cas, rat, kustreated, research, stress, model, nature, significantly, bwave, protein, number, diseases, treatment, test, treated, groups, sections, rgc, chop, error,
Topics {βοΈ}
nature portfolio privacy policy nature genetics 36 nature advertising social media monosodium iodoacetate-induced osteoarthritis pressure-induced ischaemia-reperfusion insult index 0/ reprints author information authors cell death-inducing insults pct/jp2011/067320&pct/jp2011/073160 japan research foundation er stress-induced molecule author correspondence facial nerve research er stress-reducing activities integrated medical bio-imaging nampt-dependent nad+ salvage transgenic thy1-gfp rat proteasome-mediated protein degradation joint research project flat-mounted retinal imaging light-emitting diode stimulator ganglion cell complex fewer tunel-positive cells thy1-green fluorescent protein decreased b-wave amplitude investigator-initiated clinical trial fewer chop-positive rgcs ivt-kus121βtreated group compared flat-mounted retinal images ischemia-reperfusion injured retina flat-mounted retinas treated ganglion cell layer profound anti-apoptotic effect retinal ischemia-reperfusion injury permissions 5βmg/kg body weight colorimetric-tdt enzyme assessed b-wave amplitudes vcp/p97 aaa-atpase neuronal cell death human subjects subjected anti-cleaved caspase-3 antibody induces cell death necrotic cell death gfp-positive rgc numbers japan national society
Schema {πΊοΈ}
WebPage:
mainEntity:
headline:KUS121, a VCP modulator, attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress
description:Ischemic neural damages cause several devastating diseases, including brain stroke and ischemic retinopathies, and endoplasmic reticulum (ER) stress has been proposed to be the underlying mechanism of the neuronal cell death of these conditions. We previously synthesized Kyoto University substances (KUSs) as modulators of valosin-containing protein (VCP); KUSs inhibit VCP ATPase activity and protect cells from different cell death-inducing insults. Here, we examined the efficacy of KUS121 in a rat model of retinal ischemic injury. Systemic administration of KUS121 to rats with ischemic retinal injury significantly suppressed inner retinal thinning and death of retinal ganglion and amacrine cells, with a significant functional maintenance of visual functions, as judged by electroretinography. Furthermore, intravitreal injection of KUS121, which is the clinically preferred route of drug administration for retinal diseases, appeared to show an equal or better neuroprotective efficacy in the ischemic retina compared with systemic administration. Indeed, induction of the ER stress marker C/EBP homologous protein (CHOP) after the ischemic insult was significantly suppressed by KUS121 administration. Our study suggests VCP modulation by KUS as a promising novel therapeutic strategy for ischemic neuronal diseases.
datePublished:2017-03-20T00:00:00Z
dateModified:2017-03-20T00:00:00Z
pageStart:1
pageEnd:10
license:http://creativecommons.org/licenses/by/4.0/
sameAs:https://doi.org/10.1038/srep44873
keywords:
Drug discovery
Neurological disorders
Science
Humanities and Social Sciences
multidisciplinary
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep44873/MediaObjects/41598_2017_Article_BFsrep44873_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep44873/MediaObjects/41598_2017_Article_BFsrep44873_Fig2_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep44873/MediaObjects/41598_2017_Article_BFsrep44873_Fig3_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep44873/MediaObjects/41598_2017_Article_BFsrep44873_Fig4_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep44873/MediaObjects/41598_2017_Article_BFsrep44873_Fig5_HTML.jpg
isPartOf:
name:Scientific Reports
issn:
2045-2322
volumeNumber:7
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Masayuki Hata
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
type:Organization
type:Person
name:Hanako O. Ikeda
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Chinami Kikkawa
affiliation:
name:Pharmacology Group, Non-clinical Research, Global R&D, Santen Pharmaceutical Co., Ltd
address:
name:Pharmacology Group, Non-clinical Research, Global R&D, Santen Pharmaceutical Co., Ltd, Nara, Japan
type:PostalAddress
type:Organization
type:Person
name:Sachiko Iwai
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
type:Organization
type:Person
name:Yuki Muraoka
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
type:Person
name:Tomoko Hasegawa
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
type:Person
name:Akira Kakizuka
affiliation:
name:Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies & Solution Oriented Research for Science and Technology
address:
name:Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies & Solution Oriented Research for Science and Technology, Kyoto, Japan
type:PostalAddress
type:Organization
type:Person
name:Nagahisa Yoshimura
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:KUS121, a VCP modulator, attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress
description:Ischemic neural damages cause several devastating diseases, including brain stroke and ischemic retinopathies, and endoplasmic reticulum (ER) stress has been proposed to be the underlying mechanism of the neuronal cell death of these conditions. We previously synthesized Kyoto University substances (KUSs) as modulators of valosin-containing protein (VCP); KUSs inhibit VCP ATPase activity and protect cells from different cell death-inducing insults. Here, we examined the efficacy of KUS121 in a rat model of retinal ischemic injury. Systemic administration of KUS121 to rats with ischemic retinal injury significantly suppressed inner retinal thinning and death of retinal ganglion and amacrine cells, with a significant functional maintenance of visual functions, as judged by electroretinography. Furthermore, intravitreal injection of KUS121, which is the clinically preferred route of drug administration for retinal diseases, appeared to show an equal or better neuroprotective efficacy in the ischemic retina compared with systemic administration. Indeed, induction of the ER stress marker C/EBP homologous protein (CHOP) after the ischemic insult was significantly suppressed by KUS121 administration. Our study suggests VCP modulation by KUS as a promising novel therapeutic strategy for ischemic neuronal diseases.
datePublished:2017-03-20T00:00:00Z
dateModified:2017-03-20T00:00:00Z
pageStart:1
pageEnd:10
license:http://creativecommons.org/licenses/by/4.0/
sameAs:https://doi.org/10.1038/srep44873
keywords:
Drug discovery
Neurological disorders
Science
Humanities and Social Sciences
multidisciplinary
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep44873/MediaObjects/41598_2017_Article_BFsrep44873_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep44873/MediaObjects/41598_2017_Article_BFsrep44873_Fig2_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep44873/MediaObjects/41598_2017_Article_BFsrep44873_Fig3_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep44873/MediaObjects/41598_2017_Article_BFsrep44873_Fig4_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep44873/MediaObjects/41598_2017_Article_BFsrep44873_Fig5_HTML.jpg
isPartOf:
name:Scientific Reports
issn:
2045-2322
volumeNumber:7
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Masayuki Hata
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
type:Organization
type:Person
name:Hanako O. Ikeda
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Chinami Kikkawa
affiliation:
name:Pharmacology Group, Non-clinical Research, Global R&D, Santen Pharmaceutical Co., Ltd
address:
name:Pharmacology Group, Non-clinical Research, Global R&D, Santen Pharmaceutical Co., Ltd, Nara, Japan
type:PostalAddress
type:Organization
type:Person
name:Sachiko Iwai
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
type:Organization
type:Person
name:Yuki Muraoka
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
type:Person
name:Tomoko Hasegawa
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
type:Person
name:Akira Kakizuka
affiliation:
name:Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies & Solution Oriented Research for Science and Technology
address:
name:Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies & Solution Oriented Research for Science and Technology, Kyoto, Japan
type:PostalAddress
type:Organization
type:Person
name:Nagahisa Yoshimura
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
["Periodical","PublicationVolume"]:
name:Scientific Reports
issn:
2045-2322
volumeNumber:7
Organization:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
name:Pharmacology Group, Non-clinical Research, Global R&D, Santen Pharmaceutical Co., Ltd
address:
name:Pharmacology Group, Non-clinical Research, Global R&D, Santen Pharmaceutical Co., Ltd, Nara, Japan
type:PostalAddress
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
name:Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies & Solution Oriented Research for Science and Technology
address:
name:Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies & Solution Oriented Research for Science and Technology, Kyoto, Japan
type:PostalAddress
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Masayuki Hata
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
type:Organization
name:Hanako O. Ikeda
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
type:Organization
email:[email protected]
name:Chinami Kikkawa
affiliation:
name:Pharmacology Group, Non-clinical Research, Global R&D, Santen Pharmaceutical Co., Ltd
address:
name:Pharmacology Group, Non-clinical Research, Global R&D, Santen Pharmaceutical Co., Ltd, Nara, Japan
type:PostalAddress
type:Organization
name:Sachiko Iwai
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
type:Organization
name:Yuki Muraoka
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Tomoko Hasegawa
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Akira Kakizuka
affiliation:
name:Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies & Solution Oriented Research for Science and Technology
address:
name:Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies & Solution Oriented Research for Science and Technology, Kyoto, Japan
type:PostalAddress
type:Organization
name:Nagahisa Yoshimura
affiliation:
name:Kyoto University Graduate School of Medicine
address:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
type:PostalAddress
type:Organization
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital
address:
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
type:PostalAddress
type:Organization
PostalAddress:
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
name:Pharmacology Group, Non-clinical Research, Global R&D, Santen Pharmaceutical Co., Ltd, Nara, Japan
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
name:Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies & Solution Oriented Research for Science and Technology, Kyoto, Japan
name:Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
name:Neuroprotective Treatment Project for Ocular Diseases, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
External Links {π}(120)
- How much money does https://doi.org/10.1161%2FCIR.0b013e31823ac046 generate?
- Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22179539
- How much profit does http://scholar.google.com/scholar_lookup?&title=Heart%20disease%20and%20stroke%20statistics%E2%80%932012%20update%3A%20a%20report%20from%20the%20American%20Heart%20Association&journal=Circulation&doi=10.1161%2FCIR.0b013e31823ac046&volume=125&pages=e2-e220&publication_year=2012&author=Roger%2CVL generate?
- What's the monthly money flow for https://doi.org/10.1016%2Fj.jemermed.2012.05.005?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22818644 make?
- http://scholar.google.com/scholar_lookup?&title=Tissue%20plasminogen%20activator%20and%20stroke%3A%20review%20of%20the%20literature%20for%20the%20clinician&journal=J%20Emerg%20Med&doi=10.1016%2Fj.jemermed.2012.05.005&volume=43&pages=1149-1154&publication_year=2012&author=DeMers%2CG&author=Meurer%2CWJ&author=Shih%2CR&author=Rosenbaum%2CS&author=Vilke%2CGM's total income per month
- Income figures for https://doi.org/10.1016%2Fj.preteyeres.2003.12.001
- Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Retinal%20ischemia%3A%20mechanisms%20of%20damage%20and%20potential%20therapeutic%20strategies&journal=Prog%20Retin%20Eye%20Res&doi=10.1016%2Fj.preteyeres.2003.12.001&volume=23&pages=91-147&publication_year=2004&author=Osborne%2CNN
- What are the total earnings of https://doi.org/10.1167%2Fiovs.06-0510?
- What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17197555?
- What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Retinal%20ischemia%20and%20reperfusion%20causes%20capillary%20degeneration%3A%20similarities%20to%20diabetes&journal=Invest%20Ophthalmol%20Vis%20Sci&doi=10.1167%2Fiovs.06-0510&volume=48&pages=361-367&publication_year=2007&author=Zheng%2CL&author=Gong%2CB&author=Hatala%2CDA&author=Kern%2CTS?
- How much does https://link.springer.com/doi/10.1007/BF00155046 bring in each month?
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=817878's financial summary
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Tributary%20vein%20obstruction%3A%20pathogenesis%20and%20treatment%20of%20sequelae&journal=Doc%20Ophthalmol&doi=10.1007%2FBF00155046&volume=40&pages=339-360&publication_year=1976&author=Archer%2CDB
- What are the total earnings of https://doi.org/10.1038%2Fsj.cdd.4401365?
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14752508 generate?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Ischemia-induced%20neuronal%20cell%20death%20is%20mediated%20by%20the%20endoplasmic%20reticulum%20stress%20pathway%20involving%20CHOP&journal=Cell%20Death%20Differ&doi=10.1038%2Fsj.cdd.4401365&volume=11&pages=403-415&publication_year=2004&author=Tajiri%2CS produce monthly?
- Find out how much https://doi.org/10.1016%2Fj.neulet.2014.05.042 earns monthly
- Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24880098's earnings
- How much does http://scholar.google.com/scholar_lookup?&title=Down-regulation%20of%20GRP78%20enhances%20apoptosis%20via%20CHOP%20pathway%20in%20retinal%20ischemia-reperfusion%20injury&journal=Neurosci%20Lett&doi=10.1016%2Fj.neulet.2014.05.042&volume=575&pages=68-73&publication_year=2014&author=Li%2CH&author=Zhu%2CX&author=Fang%2CF&author=Jiang%2CD&author=Tang%2CL earn?
- How much revenue does https://doi.org/10.1016%2Fj.brainres.2009.10.025 produce monthly?
- What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19853589's gross income?
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Retinal%20ganglion%20cell%20death%20induced%20by%20endoplasmic%20reticulum%20stress%20in%20a%20chronic%20glaucoma%20model&journal=Brain%20Res&doi=10.1016%2Fj.brainres.2009.10.025&volume=1308&pages=158-166&publication_year=2010&author=Doh%2CSH&author=Kim%2CJH&author=Lee%2CKM&author=Park%2CHY&author=Park%2CCK
- Learn about the earnings of https://doi.org/10.2147%2FOPTH.S3009
- What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19668425?
- What's the financial outcome of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699777?
- http://scholar.google.com/scholar_lookup?&title=Increased%20expression%20of%20IRE1alpha%20and%20stress-related%20signal%20transduction%20proteins%20in%20ischemia-reperfusion%20injured%20retina&journal=Clin%20Ophthalmol&doi=10.2147%2FOPTH.S3009&volume=2&pages=743-752&publication_year=2008&author=Hata%2CN&author=Oshitari%2CT&author=Yokoyama%2CA&author=Mitamura%2CY&author=Yamamoto%2CS income
- Get to know what's the income of https://doi.org/10.1038%2Fsj.cdd.4400955
- Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11859409's earnings
- How much does http://scholar.google.com/scholar_lookup?&title=Identification%20of%20ter94%2C%20Drosophila%20VCP%2C%20as%20a%20modulator%20of%20polyglutamine-induced%20neurodegeneration&journal=Cell%20Death%20Differ&doi=10.1038%2Fsj.cdd.4400955&volume=9&pages=264-273&publication_year=2002&author=Higashiyama%2CH net monthly?
- How much profit does https://doi.org/10.1038%2Fng1332 generate?
- Find out how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15034582 earns monthly
- What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=Inclusion%20body%20myopathy%20associated%20with%20Paget%20disease%20of%20bone%20and%20frontotemporal%20dementia%20is%20caused%20by%20mutant%20valosin-containing%20protein&journal=Nature%20genetics&doi=10.1038%2Fng1332&volume=36&pages=377-381&publication_year=2004&author=Watts%2CGD?
- How much profit does https://doi.org/10.1016%2Fj.neuron.2010.11.036 generate?
- Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21145000
- How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032425 pull in?
- What's the revenue for http://scholar.google.com/scholar_lookup?&title=Exome%20sequencing%20reveals%20VCP%20mutations%20as%20a%20cause%20of%20familial%20ALS&journal=Neuron&doi=10.1016%2Fj.neuron.2010.11.036&volume=68&pages=857-864&publication_year=2010&author=Johnson%2CJO?
- What's the financial gain of https://doi.org/10.1016%2Fj.tibs.2011.06.001?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21741246 net monthly?
- Find out how much http://scholar.google.com/scholar_lookup?&title=Cdc48%3A%20a%20power%20machine%20in%20protein%20degradation&journal=Trends%20Biochem%20Sci&doi=10.1016%2Fj.tibs.2011.06.001&volume=36&pages=515-523&publication_year=2011&author=Stolz%2CA&author=Hilt%2CW&author=Buchberger%2CA&author=Wolf%2CDH earns monthly
- How much income is https://doi.org/10.1038%2Fncb2407 earning monthly?
- What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22298039?
- What's the revenue for http://scholar.google.com/scholar_lookup?&title=Emerging%20functions%20of%20the%20VCP%2Fp97%20AAA-ATPase%20in%20the%20ubiquitin%20system&journal=Nat%20Cell%20Biol&doi=10.1038%2Fncb2407&volume=14&pages=117-123&publication_year=2012&author=Meyer%2CH&author=Bug%2CM&author=Bremer%2CS?
- https://doi.org/10.1016%2Fj.bbamcr.2011.09.002 income
- What's the profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21945179?
- Earnings of http://scholar.google.com/scholar_lookup?&title=The%20Cdc48%20machine%20in%20endoplasmic%20reticulum%20associated%20protein%20degradation&journal=Biochim%20Biophys%20Acta&doi=10.1016%2Fj.bbamcr.2011.09.002&volume=1823&pages=117-124&publication_year=2012&author=Wolf%2CDH&author=Stolz%2CA
- What's the profit of https://doi.org/10.1038%2Fsrep05970?
- What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25096051?
- Check the income stats for http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122966
- http://scholar.google.com/scholar_lookup?&title=Novel%20VCP%20modulators%20mitigate%20major%20pathologies%20of%20rd10%2C%20a%20mouse%20model%20of%20retinitis%20pigmentosa&journal=Sci%20Rep&doi=10.1038%2Fsrep05970&volume=4&publication_year=2014&author=Ikeda%2CHO income
- How much does https://doi.org/10.1038%2Fsrep31184 net monthly?
- Learn about the earnings of http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2016NatSR...631184H
- Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27503804
- What's the income generated by http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977562 each month?
- Earnings of http://scholar.google.com/scholar_lookup?&title=Neuroprotective%20efficacies%20by%20KUS121%2C%20a%20VCP%20modulator%2C%20on%20animal%20models%20of%20retinal%20degeneration&journal=Sci%20Rep&doi=10.1038%2Fsrep31184&volume=6&publication_year=2016&author=Hasegawa%2CT
- How much money does https://doi.org/10.1001%2Farchfacial.2010.71 generate?
- How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20855773 earning monthly?
- Income figures for http://scholar.google.com/scholar_lookup?&title=A%20new%20model%20for%20facial%20nerve%20research%3A%20the%20novel%20transgenic%20Thy1-GFP%20rat&journal=Arch%20Facial%20Plast%20Surg&doi=10.1001%2Farchfacial.2010.71&volume=12&pages=315-320&publication_year=2010&author=Magill%2CCK&author=Moore%2CAM&author=Borschel%2CGH&author=Mackinnon%2CSE
- How much money does https://doi.org/10.1016%2FS0014-4835%2805%2980173-3 generate?
- How much profit is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=1483506 making per month?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Cell%20death%20in%20the%20rat%20retina%20after%20a%20pressure-induced%20ischaemia-reperfusion%20insult%3A%20an%20electron%20microscopic%20study.%20I.%20Ganglion%20cell%20layer%20and%20inner%20nuclear%20layer&journal=Exp%20Eye%20Res&doi=10.1016%2FS0014-4835%2805%2980173-3&volume=55&pages=605-613&publication_year=1992&author=Buchi%2CER generate?
- See how much https://doi.org/10.1167%2Fiovs.07-1211 makes per month
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18689704 make?
- http://scholar.google.com/scholar_lookup?&title=Imaging%20mouse%20retinal%20ganglion%20cells%20and%20their%20loss%20in%20vivo%20by%20a%20fundus%20camera%20in%20the%20normal%20and%20ischemia-reperfusion%20model&journal=Invest%20Ophthalmol%20Vis%20Sci&doi=10.1167%2Fiovs.07-1211&volume=49&pages=5546-5552&publication_year=2008&author=Murata%2CH's financial summary
- What's the profit of https://doi.org/10.1167%2Fiovs.13-13372?
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Loss%20of%20inner%20retinal%20neurons%20after%20retinal%20ischemia%20in%20rats&journal=Invest%20Ophthalmol%20Vis%20Sci&doi=10.1167%2Fiovs.13-13372&volume=55&pages=2777-2787&publication_year=2014&author=Schmid%2CH&author=Renner%2CM&author=Dick%2CHB&author=Joachim%2CSC
- What's the financial intake of https://doi.org/10.1016%2Fj.preteyeres.2007.09.003?
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18042420's total income per month
- http://scholar.google.com/scholar_lookup?&title=Rodent%20electroretinography%3A%20methods%20for%20extraction%20and%20interpretation%20of%20rod%20and%20cone%20responses&journal=Prog%20Retin%20Eye%20Res&doi=10.1016%2Fj.preteyeres.2007.09.003&volume=27&pages=1-44&publication_year=2008&author=Weymouth%2CAE&author=Vingrys%2CAJ's total income per month
- How much does https://doi.org/10.1016%2F0014-4835%2891%2990215-Z rake in every month?
- What's the income of http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=1991elpa.book.....H?
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=1743256 bring in?
- http://scholar.google.com/scholar_lookup?&title=Quantitation%20of%20ischemic%20damage%20in%20the%20rat%20retina&journal=Exp%20Eye%20Res&doi=10.1016%2F0014-4835%2891%2990215-Z&volume=53&pages=573-582&publication_year=1991&author=Hughes%2CWF's revenue stream
- Explore the financials of https://doi.org/10.1167%2Fiovs.09-4086
- Revenue of http://scholar.google.com/scholar_lookup?&title=Retinal%20protection%20from%20acute%20glaucoma-induced%20ischemia-reperfusion%20injury%20through%20pharmacologic%20induction%20of%20heme%20oxygenase-1&journal=Invest%20Ophthalmol%20Vis%20Sci&doi=10.1167%2Fiovs.09-4086&volume=51&pages=4798-4808&publication_year=2010&author=Sun%2CMH
- What's the income generated by https://doi.org/10.1016%2FS0306-3623%2897%2900359-5 each month?
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9510075's total income per month
- Learn how profitable http://scholar.google.com/scholar_lookup?&title=The%20b-wave%20of%20the%20electroretinogram%20as%20an%20index%20of%20retinal%20ischemia&journal=Gen%20Pharmacol&doi=10.1016%2FS0306-3623%2897%2900359-5&volume=30&pages=281-287&publication_year=1998&author=Block%2CF&author=Schwarz%2CM is on a monthly basis
- See how much https://doi.org/10.1056%2FNEJMe1103334 makes per month
- Financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21526924
- http://scholar.google.com/scholar_lookup?&title=Bevacizumab%20versus%20ranibizumab%20for%20AMD&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMe1103334&volume=364&pages=1966-1967&publication_year=2011&author=Rosenfeld%2CPJ's revenue stream
- How much income is https://doi.org/10.1056%2FNEJMoa1414264 earning monthly?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25692915 net monthly?
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Aflibercept%2C%20bevacizumab%2C%20or%20ranibizumab%20for%20diabetic%20macular%20edema&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1414264&volume=372&pages=1193-1203&publication_year=2015&author=Wells%2CJA
- Income figures for https://doi.org/10.1016%2FS0161-6420%2891%2932135-3
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20tolerance%20of%20intravitreal%20ganciclovir%20in%20cytomegalovirus%20retinitis%20in%20acquired%20immune%20deficiency%20syndrome&journal=Ophthalmology&doi=10.1016%2FS0161-6420%2891%2932135-3&volume=98&pages=1353-1345&publication_year=1991&author=Cochereau-Massin%2CI?
- Check the income stats for https://doi.org/10.1111%2Fj.1755-3768.2011.02247.x
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21914149 produce monthly?
- http://scholar.google.com/scholar_lookup?&title=Repeat%20intravitreal%20triamcinolone%20acetonide%20injections%20in%20uveitic%20macular%20oedema&journal=Acta%20Ophthalmol&doi=10.1111%2Fj.1755-3768.2011.02247.x&volume=90&pages=e323-325&publication_year=2012&author=Sallam%2CA income
- Income figures for https://citation-needed.springer.com/v2/references/10.1038/srep44873?format=refman&flavour=references
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Masayuki%20Hata generate?
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Masayuki%20Hata%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's total income per month
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hanako%20O.%20Ikeda bring in?
- Check the income stats for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hanako%20O.%20Ikeda%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chinami%20Kikkawa gross monthly?
- Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chinami%20Kikkawa%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- Financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sachiko%20Iwai
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sachiko%20Iwai%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en net monthly?
- Income figures for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yuki%20Muraoka
- What's the profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yuki%20Muraoka%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What's the monthly income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tomoko%20Hasegawa?
- See how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tomoko%20Hasegawa%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en makes per month
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Akira%20Kakizuka's total income per month
- How much income does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Akira%20Kakizuka%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have?
- What's the financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Nagahisa%20Yoshimura?
- What is the monthly revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Nagahisa%20Yoshimura%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much does https://static-content.springer.com/esm/art%3A10.1038%2Fsrep44873/MediaObjects/41598_2017_BFsrep44873_MOESM49_ESM.pdf generate monthly?
- What's the total monthly financial gain of http://creativecommons.org/licenses/by/4.0/?
- How much does https://s100.copyright.com/AppDispatchServlet?title=KUS121%2C%20a%20VCP%20modulator%2C%20attenuates%20ischemic%20retinal%20cell%20death%20via%20suppressing%20endoplasmic%20reticulum%20stress&author=Masayuki%20Hata%20et%20al&contentID=10.1038%2Fsrep44873©right=The%20Author%28s%29&publication=2045-2322&publicationDate=2017-03-20&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY bring in each month?
- What's the income generated by https://crossmark.crossref.org/dialog/?doi=10.1038/srep44873 each month?
- How much does https://citation-needed.springer.com/v2/references/10.1038/srep44873?format=refman&flavour=citation gross monthly?
- What's https://doi.org/10.1038/s41420-022-01007-3's gross income?
- https://doi.org/10.1038/s41598-022-20497-w's revenue stream
- How much does https://doi.org/10.1038/s41598-021-95173-6 pull in monthly?
- How much revenue does https://doi.org/10.1038/s41598-020-61160-6 bring in?
- What are the total earnings of https://doi.org/10.1038/s41598-020-77735-2?
- How much does https://www.protocols.io/ rake in every month?
- Explore the financials of https://www.natureindex.com/
- What are the earnings of http://www.naturechina.com?
- How profitable is https://www.natureasia.com/ja-jp?
Analytics and Tracking {π}
- Google Tag Manager
Libraries {π}
- Prism.js
- Zoom.js
Emails and Hosting {βοΈ}
Mail Servers:
- mxa-002c5801.gslb.pphosted.com
- mxb-002c5801.gslb.pphosted.com
Name Servers:
- pdns1.ultradns.net
- pdns2.ultradns.net
- pdns3.ultradns.org
- pdns4.ultradns.org
- pdns5.ultradns.info
- pdns6.ultradns.co.uk
CDN Services {π¦}
- Crossref